. home.aspx
EVENTS
Pharmacoepidemiology & Therapeutic Risk Management
PHARMACOEPIDEMIOLOGY & THERAPEUTIC RISK MANAGEMENT
August 26-30, 2020
36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) is organized by International Society for Pharmacoepidemiology (ISPE) and will be held from Aug 26 - 30, 2020 at Estrel Berlin, Berlin, Germany.

Drug Metabolism
DRUG METABOLISM
July 12-17, 2020
Drug Metabolism focuses on predicting drug metabolism using P450 structural information and aims to address a wide range of other relevant themes. The conference program will comprise of a keynote lecture, four morning and three evening sessions and poster sessions and it will be a coherent fusion o...

2020 AACA Annual Meeting
2020 AACA ANNUAL MEETING
June 15-19, 2020
The American Association of Clinical Anatomists is the international home for the advancement of clinical anatomy knowledge and anatomical services through education, research and scholarship.

C-SUITE ON DECK

Performance Marketing Q&A With Gary Skidmore, CEO Of Aberdeen Group

December 12, 2016 / Staff Writer
We spoke with Gary Skidmore, the CEO of the Aberdeen Group, and asked him to share his insights on lead velocity and marketing performance.  Gary has a well-established track-record of innovation in marketing acceleration from his time as a small business entrepreneur, global company executive and currently as CEO at the Aberdeen Group.

Here are his thoughts on what he’s seen work when it comes to sales and marketing speed.

DECK 7: What do you see as major impediments to marketing performance and ultimately more leads?GARY SKIDMORE: Simply put, marketers continue to get bogged down when they don’t have a clear understanding of who their best customers are, how they think and then what type of information might be most useful for them. When it comes to understanding customers, clarity helps to focus all marketing acceleration efforts (and related lead quantity and quality) on the things that matter to your customer.  That’s a good thing.

D 7: How are leading companies addressing the issue of performance and velocity? GS: We see, from our Aberdeen Group research, that many companies continue to invest in data, predictive tools, 

"Performance marketing requires a precise understanding of where to spend your valuable resources along with what to do to accelerate engagement."

content and other marketing technologies to try and solve the issue of performance. However, one of the problems is that while all these tools are great, they usually don't work unless you have some level of integration. For example, data is needed, but how do you align that data by segment with a message? Then, once you identify a trending message, how do you ensure that the content you’re creating actually gets noticed and can drive engagement fast. Best-in-class companies are ones that are integrating data, targeting, messaging and content into one continuous workflow.

D 7: What new innovations are making the scene to help marketers get results faster? GS: There are a number of companies that have launched over the last 12 to 24 months that address data and content discreetly. Regarding data tools, many of these new platforms talk about how you might “predict” who’s about to purchase.  The content and messaging tools might also give you the ability to create and distribute content more readily internally and externally. However, as mentioned above, sometimes these individual technologies don’t go far enough.

Where does Aberdeen play in helping clients improve their marketing velocity? We’re a company spending the majority of our time building solutions that integrate advanced data, machine learning and aligned content to help companies know who to approach first and what to say to them to drive accelerated engagement. Our data and content platform, Lead Essentials, does just that by aligning the best in-market accounts with content that is guaranteed to get them to engage. We've integrated these important functions into one platform and workflow. We’re changing the way marketing works and speeding up the process and related effectiveness significantly. In other words, more conversion and more leads, faster.


D 7: Who are your current customers and how does one take advantage of your solutions (both end users and partners)? GS: Lead Essentials, as well as our other products and services are right for just about any mid to large-size B2B organization. We don't just help organizations find more leads, we give them a fuller picture of who they are, how to reach them and how to get them engaged. We offer a SAAS model with our integrated data and content solution, as well as other ways to engage with us for more custom work. We are aggressively looking for ways to partner with other like-minded technology, data or content providers to help fuel their businesses with our unique data and content assets. To find out more about Aberdeen, visit us at www.aberdeenservices.com


About Aberdeen Group


Aberdeen Group is a technology and services company that helps tech sales and marketing executives distill smart data science into actionable moments. Aberdeen helps companies win through their unique targeting capabilities (using the CI Technology Data Set), advanced analytics using their own innovative proprietary and public data sources, and their original and research based content engine.

For more information on Aberdeen’s leading data and content platform, Lead Essentials, check out the demo here. If you’re looking for ideas, check out the Aberdeen idea book, chock full of ways that you can use our data and content for your own marketing programs.

You may also be interested in Aberdeen’s latest Guidebook on Account-Based Targeting. Find out new ways to think about what accounts need to be in your account-based sales and marketing programs.  Enjoy!

RELATED NEWS


Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced today that Karen Sheehy, J.D., has been appointed to serve as the company’s Senior Vice President and Chief Compliance Officer. As part of a long-planned transition, current Chief Compliance Officer Raymond Furey has recruited an expanded Compliance team and this new leader to be co-located with Mallinckrodt’s growing New Jersey-based Specialty Brands business, and he will now pursue new opportunities in Californ...
WWW.MALLINCKRODT.COM
READ MORE

These observations have led to the creation of a new specialty DSO, OMS Logistics (OMSL), http://www.omslogistics.com that has built a platform to offer turnkey oral surgery and general anesthesia services to large dental groups and DSO’s. OMSL was launched in 2018 in Nashville, TN to build upon years of mobile oral surgery experience but modified to be able to partner with other DSO’s. In 2019, the company expanded to 14 locations in Middle and East Tennessee with the goal of becomi...

READ MORE

Sanofi’s strategy of betting on new drugs and biotech acquisitions seems to be paying off, as the company has forecast growth for 2019 thanks to higher than expected quarterly earnings and strong sales at Genzyme. The company forecast a 3-5% increase in earnings per share for 2019. Patent expiries in diabetes drugs like Lantus have taken their toll on previous earnings, and in the latest quarter sales in diabetes and cardiovascular unit fell 11.3%. However sales at Genzyme rose 37.4%, and ...

READ MORE

Neem Biotech, the Welsh-based fundamental Research and Development arm of the Zaluvida group of life science companies, was pleased to present the work into development of a novel mode of action as an adjunct to existing antibiotics at the North American Cystic Fibrosis Conference Indiana, USA from 2nd November 2017 to 4th of November 2017....

READ MORE

For the first time, patients with a rare and life-threatening blood disorder have a treatment option after Novartis’ Rydapt got an EU licence for aggressive systemic mastocytosis, related blood cancers, and acute myeloid leukaemia....

READ MORE

Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its wholly-owned subsidiary, Armstrong Pharmaceuticals, Inc., for its New Drug Application for Primatene® Mist (epinephrine inhalation aerosol)…...
NASDAQ STOCK MARKET
READ MORE

RESOURCES

home.aspx
   

EVENTS

Pharmacoepidemiology & Therapeutic Risk Management
PHARMACOEPIDEMIOLOGY & THERAPEUTIC RISK MANAGEMENT
August 26-30, 2020
36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) is organized by International Society for Pharmacoepidemiology (ISPE) and will be held from Aug 26 - 30, 2020 at Estrel Berlin, Berlin, Germany.

Drug Metabolism
DRUG METABOLISM
July 12-17, 2020
Drug Metabolism focuses on predicting drug metabolism using P450 structural information and aims to address a wide range of other relevant themes. The conference program will comprise of a keynote lecture, four morning and three evening sessions and poster sessions and it will be a coherent fusion o...

2020 AACA Annual Meeting
2020 AACA ANNUAL MEETING
June 15-19, 2020
The American Association of Clinical Anatomists is the international home for the advancement of clinical anatomy knowledge and anatomical services through education, research and scholarship.